Related Experiment Videos
Angiogenesis Inhibitors in NSCLC.
Anna Manzo1, Agnese Montanino2, Guido Carillio3
1Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS, 80131 Napoli, Italy. anna_manzo1@hotmail.it.
International Journal of Molecular Sciences
|September 22, 2017
Summary
Bevacizumab was the first angiogenesis inhibitor for non-small cell lung cancer (NSCLC). Newer agents like ramucirumab and nintedanib show survival benefits in second-line NSCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Angiogenesis is crucial for non-small cell lung cancer (NSCLC) growth and metastasis.
- Bevacizumab, an early angiogenesis inhibitor, had limitations in NSCLC treatment.
- Recent advancements show promise for new antiangiogenic agents in NSCLC therapy.
Purpose of the Study:
- To review the role of angiogenesis inhibitors in NSCLC treatment.
- To highlight the efficacy of newer agents like ramucirumab and nintedanib.
- To discuss the challenges in identifying predictive biomarkers for antiangiogenic therapy.
Main Methods:
- Review of clinical trial data for angiogenesis inhibitors in NSCLC.
- Analysis of progression-free survival (PFS) and overall survival (OS) data.
- Comparison of treatment outcomes across different antiangiogenic agents and patient populations.
Main Results:
- Bevacizumab demonstrated modest PFS and OS improvements in first-line NSCLC.
- Ramucirumab and nintedanib showed significant survival benefits in second-line NSCLC.
- Nintedanib demonstrated improved OS in adenocarcinoma histology NSCLC.
Conclusions:
- Ramucirumab and nintedanib represent new options for second-line NSCLC treatment.
- The development of predictive biomarkers is essential for optimizing antiangiogenic therapy.
- Further research is needed to personalize NSCLC treatment with angiogenesis inhibitors.